Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung



Study Overview

The purpose of this study is to evaluate the amount of radiation used in stereotactic ablative ratiotherapy (SABR). This study asks if patients with non-small cell lung cancer of the lung squamous cell subtype can safely receive more radiation. If a higher radiation dose is found to be safe, the study then asks if that higher dose can control the cancer better than the current standard dose.


Study Description

The purpose of this study is to evaluate the amount of radiation used in stereotactic ablative ratiotherapy (SABR). This study asks if patients with non-small cell lung cancer of the lung squamous cell subtype can safely receive more radiation. If a higher radiation dose is found to be safe, the study then asks if that higher dose can control the cancer better than the current standard dose.

Additional Information:

Participants will not be paid for their participation.



Research Study Identifier: TX8196
ClinicalTrials.gov Identifier: NCT1706985235 (IUSCC-0624)
Principal Investigator: Tim Lautenschlaeger, MD


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.